佐力药业：公司药品生产许可证变更

Core Viewpoint - Zhaoli Pharmaceutical has received a revised "Drug Production License" from the Zhejiang Provincial Drug Administration, which includes changes in key personnel and the addition of new production lines to enhance production capacity and quality management [1] Group 1: License Changes - The quality responsible person has been changed from Xia Zhanqiang to Peng Xiaoguo [1] - The quality authorizers have been updated to include Peng Xiaoguo and Fang Mingchun, replacing Xia Zhanqiang [1] - The production responsible person has been changed from Peng Xiaoguo to Zhu Xiaoping [1] Group 2: New Production Facilities - New workshops and production lines have been added, including the 106 workshop's capsule production line, the 204 pre-treatment workshop, and additional lines for tablets and granules [1] - The production scope now includes hard capsules, tablets, and granules, which will help optimize production layout and meet market demand [1] Group 3: Impact on Operations - The changes are expected to improve production and quality management, enhance capacity, and refine product structure [1] - There is no significant impact on the company's performance anticipated from these changes [1]